Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.9433
- Book/Share 32.6431
- PB 6.2848
- Debt/Equity 0.0806
- CurrentRatio 1.0736
- ROIC 0.1293
- MktCap 494278936651.0
- FreeCF/Share 7.8498
- PFCF 25.9273
- PE 19.8352
- Debt/Assets 0.0331
- DivYield 0.0251
- ROE 0.3269
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | JNJ | Scotiabank | -- | Sector Outperform | -- | $230 | Nov. 13, 2025 |
| Upgrade | JNJ | Daiwa Securities | Neutral | Outperform | -- | $203 | Oct. 20, 2025 |
| Upgrade | JNJ | Wells Fargo | Equal Weight | Overweight | -- | $212 | Oct. 3, 2025 |
| Upgrade | JNJ | Guggenheim | Neutral | Buy | -- | $206 | Sept. 23, 2025 |
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.
Read More
J&J's Innovative Medicine Segment in Q4: Here's What to Watch
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.
Read More
JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance the drug into phase III.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
JNJ vs. AZN: Which Drug Stock Comes Out on Top for Investors?
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion.
Read More
Want Decades of Passive Income? 2 Stocks to Buy Right Now
Published: January 01, 2026 by: The Motley Fool
Sentiment: Positive
These businesses are profitable with durable competitive advantages. Johnson & Johnson is one of the leading pharmaceutical companies.
Read More
Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Best Dividend Aristocrats For January 2026
Published: December 31, 2025 by: Seeking Alpha
Sentiment: Positive
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.
Read More
The Big 3: JNJ, SNDK, TWLO
Published: December 30, 2025 by: Schwab Network
Sentiment: Neutral
Healthcare, storage chips, and software adding AI integration take the focus of Tuesday's Big 3. Jenny Horne and Rick Ducat turn to technical analysis in Johnson & Johnson (JNJ), SanDisk (SNDK), and Twilio (TWLO).
Read More
Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now
Published: December 30, 2025 by: Investopedia
Sentiment: Positive
CNBC's "Mad Money" host is waving the yellow flag.
Read More
3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.
Read More
Top 5 High-Yield S&P 500 Stocks to Buy for 2026
Published: December 29, 2025 by: Zacks Investment Research
Sentiment: Positive
High-yield S&P 500 stocks are gaining traction for 2026 as AI investment accelerates and investors seek income amid trade and geopolitical uncertainty.
Read More
Can J&J's Pipeline Progress in 2025 Aid Long-Term Growth?
Published: December 26, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's rapidly advancing pipeline, new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade.
Read More
Dogs of the Dow Beat the Market in 2025 — Here's the Smarter 4-Stock Play for 2026
Published: December 25, 2025 by: 24/7 Wall Street
Sentiment: Positive
Keeping things simple when investing is often best, which is why buying an index fund can be the optimal strategy.
Read More
J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling
Published: December 23, 2025 by: New York Post
Sentiment: Negative
The plaintiff's law firm said was the largest-ever sum awarded against J&J for a single plaintiff.
Read More
JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson wins EU approval for Tremfya in pediatric plaque psoriasis, making it the first IL-23 inhibitor cleared for any pediatric condition.
Read More
Stormy 2026? 3 Defensive Stocks to Weather a Recession
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
TPB, JNJ and NEE highlight how defensive stocks can offer stability and steady growth potential amid rising uncertainty for 2026.
Read More
5 Big Drug Stocks That May Continue to Outperform in 2026
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
Read More
J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J has been trading above its 50- and 200-day SMAs for six months as strong 2025 execution, new drugs and pipeline progress support bullish momentum.
Read More
Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson
Published: December 19, 2025 by: Business Wire
Sentiment: Neutral
ST. PAUL, Minn.--(BUSINESS WIRE)--A Minnesota jury awarded $65.5 million to a 37-year-old mother of three minor children after finding in her favor in a lawsuit against Johnson & Johnson, concluding that the company's talc products exposed her to asbestos and contributed to her developing mesothelioma, a cancer of the lining of the lungs. The verdict follows a 13-day trial in Ramsey County District Court, where jurors heard evidence that Johnson & Johnson sold and marketed talc-based co.
Read More
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
Read More
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
Read More
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a first-of-its-kind precision combo.
Read More
US FDA grants priority voucher to J&J's blood cancer treatment
Published: December 15, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration said on Monday it has granted a national priority voucher to Johnson & Johnson's treatment for a type of blood cancer, bringing the total number of products receiving an award under the program to 16 this year.
Read More
Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.
Read More
The 5 Best S&P 500 Dividend Aristocrat Stocks to Buy Before 2026
Published: December 09, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love S&P 500 dividend stocks, especially those with dependable, high yields, because they provide a substantial passive income stream and offer significant total return potential.
Read More
Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Negative
J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth to stay on track.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100